These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 20861143

  • 1. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study.
    Rebora P, Czene K, Antolini L, Gambacorti Passerini C, Reilly M, Valsecchi MG.
    Am J Epidemiol; 2010 Nov 01; 172(9):1028-33. PubMed ID: 20861143
    [Abstract] [Full Text] [Related]

  • 2. Merkel cell carcinoma: incidence, mortality, and risk of other cancers.
    Kaae J, Hansen AV, Biggar RJ, Boyd HA, Moore PS, Wohlfahrt J, Melbye M.
    J Natl Cancer Inst; 2010 Jun 02; 102(11):793-801. PubMed ID: 20424236
    [Abstract] [Full Text] [Related]

  • 3. Second cancers following the diagnosis of Merkel cell carcinoma: a nationwide cohort study.
    Koljonen V, Kukko H, Tukiainen E, Böhling T, Sankila R, Joensuu H, Pukkala E.
    Cancer Epidemiol; 2010 Feb 02; 34(1):62-5. PubMed ID: 20061203
    [Abstract] [Full Text] [Related]

  • 4. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
    Huang KP, Weinstock MA, Clarke CA, McMillan A, Hoppe RT, Kim YH.
    Arch Dermatol; 2007 Jan 02; 143(1):45-50. PubMed ID: 17224541
    [Abstract] [Full Text] [Related]

  • 5. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
    Gunnarsson N, Stenke L, Höglund M, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Richter J, Wadenvik H, Wallvik J, Själander A.
    Br J Haematol; 2015 Jun 02; 169(5):683-8. PubMed ID: 25817799
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study.
    Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Tracey E, Sankila R, Weiderpass E, Olsen JH, McBride ML, Brewster DH, Pompe-Kirn V, Kliewer EV, Chia KS, Tonita JM, Martos C, Jonasson JG, Merletti F, Boffetta P.
    J Natl Cancer Inst; 2007 May 16; 99(10):790-800. PubMed ID: 17505074
    [Abstract] [Full Text] [Related]

  • 8. Risk of a second malignant neoplasm among 5-year survivors of cancer in childhood and adolescence in British Columbia, Canada.
    MacArthur AC, Spinelli JJ, Rogers PC, Goddard KJ, Phillips N, McBride ML.
    Pediatr Blood Cancer; 2007 Apr 16; 48(4):453-9. PubMed ID: 16767718
    [Abstract] [Full Text] [Related]

  • 9. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
    Yin XF, Wang JH, Li X, Yu MX, Ma ZX, Jin J.
    Clin Lymphoma Myeloma Leuk; 2016 Oct 16; 16(10):577-581. PubMed ID: 27397576
    [Abstract] [Full Text] [Related]

  • 10. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation.
    Tuohimaa P, Pukkala E, Scélo G, Olsen JH, Brewster DH, Hemminki K, Tracey E, Weiderpass E, Kliewer EV, Pompe-Kirn V, McBride ML, Martos C, Chia KS, Tonita JM, Jonasson JG, Boffetta P, Brennan P.
    Eur J Cancer; 2007 Jul 16; 43(11):1701-12. PubMed ID: 17540555
    [Abstract] [Full Text] [Related]

  • 11. Uveal melanoma: a study on incidence of additional cancers in the Swedish population.
    Bergman L, Nilsson B, Ragnarsson-Olding B, Seregard S.
    Invest Ophthalmol Vis Sci; 2006 Jan 16; 47(1):72-7. PubMed ID: 16384946
    [Abstract] [Full Text] [Related]

  • 12. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.
    Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE.
    J Natl Cancer Inst; 2008 Dec 17; 100(24):1771-9. PubMed ID: 19066271
    [Abstract] [Full Text] [Related]

  • 13. Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia.
    Brennan P, Coates M, Armstrong B, Colin D, Boffetta P.
    Br J Cancer; 2000 Apr 17; 82(7):1344-7. PubMed ID: 10755412
    [Abstract] [Full Text] [Related]

  • 14. Second primary cancers in patients with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries.
    Scélo G, Boffetta P, Corbex M, Chia KS, Hemminki K, Friis S, Pukkala E, Weiderpass E, McBride ML, Tracey E, Brewster DH, Pompe-Kirn V, Kliewer EV, Tonita JM, Martos C, Jonasson JG, Brennan P.
    Cancer Causes Control; 2007 Apr 17; 18(3):269-78. PubMed ID: 17237987
    [Abstract] [Full Text] [Related]

  • 15. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
    Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto KJ, Fujita H, Fujioka I, Kimura Y, Aisa Y, Iwanaga E, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T.
    Med Oncol; 2018 May 30; 35(7):99. PubMed ID: 29846829
    [Abstract] [Full Text] [Related]

  • 16. Risk of second primary malignancies in women with papillary thyroid cancer.
    Canchola AJ, Horn-Ross PL, Purdie DM.
    Am J Epidemiol; 2006 Mar 15; 163(6):521-7. PubMed ID: 16421240
    [Abstract] [Full Text] [Related]

  • 17. A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia.
    Miettinen M, Kraszewska E, Sobin LH, Lasota J.
    Cancer; 2008 Feb 01; 112(3):645-9. PubMed ID: 18041070
    [Abstract] [Full Text] [Related]

  • 18. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M.
    Cancer; 2003 Oct 01; 98(7):1430-7. PubMed ID: 14508830
    [Abstract] [Full Text] [Related]

  • 19. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study.
    Spanogle JP, Clarke CA, Aroner S, Swetter SM.
    J Am Acad Dermatol; 2010 May 01; 62(5):757-67. PubMed ID: 20223559
    [Abstract] [Full Text] [Related]

  • 20. The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.
    Hasford J, Pfirrmann M, Shepherd P, Guilhot J, Hehlmann R, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Steegmann JL, Thaler J.
    Haematologica; 2005 Mar 01; 90(3):335-40. PubMed ID: 15749665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.